Placebo News and Research

RSS

Brain network measures placebo effects in Parkinson's disease patients

Investigators at The Feinstein Institute for Medical Research have utilized a new image-based strategy to identify and measure placebo effects in randomized clinical trials for brain disorders. The findings are published in the August issue of The Journal of Clinical Investigation.

19 Jul 2014

Consumption of probiotics during 30 days helps diminish accumulation of fat in liver

Spanish scientists have demonstrated through an experiment on obese rats that the consumption of probiotics during thirty days helps diminish the accumulation of fat in the liver.

18 Jul 2014

Phase II study reveals potential biomarker for HIV vaccine

Further analysis of a Phase II study of therapeutic HIV vaccine candidate Vacc-4x revealed a potential biomarker associated with participants who experienced a more profound viral load reduction after receiving the vaccine.

18 Jul 2014

Ipsen’s Somatuline CLARINET Phase III study published online in NEJM

The U.S. affiliate of Ipsen today announced that the New England Journal of Medicine has published clinical trial results showing that Somatuline Autogel / Somatuline Depot (lanreotide) Injection 120 mg (referred to as Somatuline) achieved statistically significant prolongation of progression free survival (PFS) over placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

17 Jul 2014

Phase 2 dose-ranging study of AYX1 for prevention of post-surgical pain

Adynxx, developer of a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the first patient was dosed in ADYX-003, a Phase 2 dose-ranging study of AYX1, an investigational drug candidate for the prevention of post-surgical pain.

17 Jul 2014

Phase III research shows that new drug improves symptoms related to plaque psoriasis

Randomized, phase III research from the University of Alabama at Birmingham shows that a new drug improves symptoms related to moderate to severe plaque psoriasis, a chronic skin disease of scaling and inflammation.

17 Jul 2014

Isis earns $1 million payment from GSK related to advancement of ISIS-TTRRx

Isis Pharmaceuticals, Inc. announced today that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).

16 Jul 2014

Rigel initiates Phase 3 clinical program for fostamatinib in patients with ITP

Rigel Pharmaceuticals, Inc. today announced the initiation of a Phase 3 clinical program for its oral SYK inhibitor, fostamatinib, in patients with ITP (immune thrombocytopenic purpura).

16 Jul 2014

Hydroxychloroquine treatment not effective for primary Sjögren syndrome

Among patients with the systemic autoimmune disease primary Sjögren syndrome, use of hydroxychloroquine, the most frequently prescribed treatment for the disorder, did not improve symptoms during 24 weeks of treatment compared with placebo, according to a study in the July 16 issue of JAMA.

16 Jul 2014

‘No convincing evidence’ for zinc supplements to prevent otitis media

There is no convincing evidence that zinc supplements reduce the risk of otitis media in children or adults, say the authors of an updated Cochrane review.

15 Jul 2014

B vitamins do not prevent Alzheimer's disease

Taking B vitamins doesn't slow mental decline as we age, nor is it likely to prevent Alzheimer's disease, conclude Oxford University researchers who have assembled all the best clinical trial data involving 22,000 people to offer a final answer on this debate.

15 Jul 2014

Paracetamol safety and osteoarthritis: an interview with Professor David Hunter, University of Sydney

Firstly, paracetamol has been the first-line recommended treatment for osteoarthritis pain for very many years and, secondly, it is readily available over the counter and can be bought in relatively large quantities.

15 Jul 2014

BAI and Novartis determine whether investigational drugs can prevent symptoms of Alzheimer's

Researchers from the Banner Alzheimer's Institute (BAI) today announced a partnership with Novartis in a pioneering medical trial to determine whether two investigational anti-amyloid drugs-an active immunotherapy and an oral medication-can prevent or delay the emergence of symptoms of Alzheimer's in people at particularly high risk for developing the disease at older ages.

15 Jul 2014

CRAG urges researchers to balance goal of shortening treatment for MDR-TB with patient safety

In a viewpoint published this week in The Lancet, the Community Research Advisors Group argue that research into bedaquiline – a new drug, fast tracked for multidrug-resistant tuberculosis (MDR-TB) – should proceed cautiously in people with drug-sensitive tuberculosis.

14 Jul 2014

CYD-TDV vaccine shows moderate protection against dengue in Asian children

The first dengue vaccine candidate (CYD-TDV) to reach phase 3 clinical testing has shown moderate protection (56%) against the disease in Asian children, according to new research published in The Lancet.

14 Jul 2014

Can-Fite's CF102 drug gets approval in Israel for patient with hepatocellular carcinoma

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the Israeli Ministry of Health has approved the use of its drug CF102 for a patient with hepatocellular carcinoma, the most common form of liver cancer, under the country's Compassionate Use Program.

10 Jul 2014

Pharmalink’s core patents for Nefecon issued in United States, Europe, China and Hong Kong

Pharmalink AB, a specialty pharma company focused on orphan and niche products, has had core patents for its late-stage clinical candidate Nefecon® issued in the key markets United States, Europe, China and Hong Kong. A patent is pending in Japan.

10 Jul 2014

NIAID launches CRS3123 Phase I trial to treat C. difficile infection

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has launched an early-stage clinical trial of CRS3123, an investigational oral antibiotic intended to treat Clostridium difficile (C. difficile) infection.

10 Jul 2014

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema.

10 Jul 2014

Pain control in osteoarthritis patients

Osteoarthritis (OA) is one of the most common causes of disability, and inadequate pain control can lead to joint stiffness that may impair mobility for patients.

9 Jul 2014

Placebo News and Research

Brain network measures placebo effects in Parkinson's disease patients

Consumption of probiotics during 30 days helps diminish accumulation of fat in liver

Phase II study reveals potential biomarker for HIV vaccine

Ipsen’s Somatuline CLARINET Phase III study published online in NEJM

Phase 2 dose-ranging study of AYX1 for prevention of post-surgical pain

Phase III research shows that new drug improves symptoms related to plaque psoriasis

Isis earns $1 million payment from GSK related to advancement of ISIS-TTRRx

Rigel initiates Phase 3 clinical program for fostamatinib in patients with ITP

Hydroxychloroquine treatment not effective for primary Sjögren syndrome

‘No convincing evidence’ for zinc supplements to prevent otitis media

B vitamins do not prevent Alzheimer's disease

Paracetamol safety and osteoarthritis: an interview with Professor David Hunter, University of Sydney

BAI and Novartis determine whether investigational drugs can prevent symptoms of Alzheimer's

CRAG urges researchers to balance goal of shortening treatment for MDR-TB with patient safety

CYD-TDV vaccine shows moderate protection against dengue in Asian children

Can-Fite's CF102 drug gets approval in Israel for patient with hepatocellular carcinoma

Pharmalink’s core patents for Nefecon issued in United States, Europe, China and Hong Kong

NIAID launches CRS3123 Phase I trial to treat C. difficile infection

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Pain control in osteoarthritis patients

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News